New Collaborative Initiative To Deliver Tailored Support For RCTs In Low Resource Settings

Clinical trial networks around the world have teamed up to promote good randomized control trials in low- and middle-income countries. They plan to focus on multiple health challenges and diverse contexts.

Items to be used in a clinical trial to test a potential vaccine for COVID19 coronavirus.
Low- and middle-income countries face unique challenges in conducting RCTs • Source: Shutterstock

Four major clinical trial networks operating in Latin America, Southeast Asia and South Africa have joined forces with the global non-profit Good Clinical Trials Collaborative (GCTC) to strengthen the clinical trials systems in their respective regions.

The other four partners involved in the new initiative, called the Good Trials Prism, are the ADVANcing Clinical Evidence in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from International

More from Geography

‘Unprecedented Story’: Revoked EU Marketing Authorization Fails To Thwart Translarna Sales

 

PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By 

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Valneva Expects UK And France to Lift Ixchiq Age Restriction Following EMA Decision

 

Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.